From 2011.igem.org

Revision as of 23:08, 20 September 2011

• Project
• Team
• Modelling
• Human Practices
• Project Safety
• Acknowledgements

• Project Summary
• Lab Books
• Results
• Parts

• Meet the Team
• Team Vlog
• Photo Gallery

• Modelling
• Tutorial

• Human Practices

• Safety Overview
• Biobricks

• Acknowledgements
• Attributions

Safety

Safety Questions

Question 1:

It was decided at an early stage of our project that we would work with biofilms. This meant examining a number of organisms that are able to form biofilms, could be made transformable and are safe to use. We quickly decided E. coli Nissle 1917 were the safest biofilm forming organisms to work with. During investigative research we found that the lab-strains of E. coli, Top 10 and DS941, whilst being non-pathogenic, had lost the ability to form biofilms.

We also had access to three bacterial strains of the class Pseudomonas: (P. aeruginosa, P. putida and P. fluorescens). Whilst having a well-documented ability to form biofilms, P. aeruginosa is also classed as a level 2 biosafety organism; therefore precautions must be taken to prevent percutaneous, ingestion and mucous membrane exposure to clinical materials - as per BSL2 recommendations and Occupational Safety and Health Administration requirements.

This meant that we had to carefully consider the safety of all researchers before we began working with Pseudomonas strains. We consulted a number of guidelines as well as the Administration Technician for the building regarding working with BSL2 organisms. We also had a meeting with a Professor from our Microbiology Institute who advised us on working with Pseudomonas aeruginosa and gave us a brief safety talk. In line with these guidelines, all work with Pseudomonas was carried out:

o After all participants had been shown the proper way of handling and disposing of the organisms and contaminated material
o Only under supervision of experienced personnel
o In a part of the building that was not accessible to the public
o No contact lenses were worn in the lab

This was in addition to standard laboratory safety measures, such as wearing lab coats, gloves and full decontamination of work surfaces.

In addition to working within the safety guidelines for Pseudomonas aeruginosa, where possible, we worked with P.putida or E. coli Nissle 1917 (that are able to form biofilms) both of which are less pathogenic than Pseudomonas aeruginosa.

Latherin

One of the novel biobricks we were working on was latherin. Latherin is a protein originating from horses which can potentially cause allergic reactions in humans; we therefore ensured none of the team members was allergic to horses. Also, any work carried out using the protein was kept in sealed and labelled containers.

b).Risks to the safety and health of the general public if released by design or accident?

It is important to note that we have been working in a lab with restricted access, meaning it cannot be entered by unauthorised personnel. Nevertheless, we carefully considered the possible safety risks to the public in the event of accidental or deliberate release of any aspect of our project.

The organisms we have been working with are lab strains which are unlikely to be able to survive outside of the laboratory environment. We have also been working with E. coli Nissle 1917 cells which are available in probiotic formulation, Mutaflor, in several countries and are therefore not deemed a serious risk.

We do not expect that any of our biobricks would cause harm to the general public if released. This is considered more in our Biobrick Safety page, which can be accessed here.

Therefore, we do not expect that any aspect of our project (biobrick or organism) could pose a danger to the safety or health of the general public.

c). Risks to environmental quality if released by design or accident?

We do not expect that any of our novel biobricks would pose a risk to the environment.

This is considered more in our Biobrick Safety page, which can be accessed here

d). Risks to security through malicious misuse by individuals, groups or states?

Given the nature of our project, we do not anticipate any way it could be used maliciously.

As discussed above, latherin can cause allergic reactions in humans and therefore should be labelled appropriately.

If your response to any of the questions above is yes:

a. Explain how you addressed these issues in project design and while conducting laboratory work.

Before working with latherin we asked all participants if they had a known allergen to horses. We then read a report from the Department of Human Services Allergy Working Party to the Minister for Health on Allergens and Anaphylaxis from 2009 and kept contact with the substance to a minimum throughout.

b.Describe and document safety, security, health and/or environmental issues as you submit your parts to the Registry.

We plan to have easily accessible documents containing all information relevant to our submitted biobricks. These will contain our safety information, sequences and relevant testing data and will be available as links on the registry page.

We will update this section in the event that new safety information arises in the process of submitting parts to the Registry. We do not anticipate this happening.

Under what biosafety provisions will / do you operate?

Does your institution have its own biosafety rules and if so what are they? Provide a link to them online if possible.

University of Glasgow has its own biosafety guidelines. These have been set out by the Safety & Environmental Protection Services. They are accessible here/

b) Does your institution have an Institutional Biosafety Committee or equivalent group? If yes, have you discussed your project with them? Describe any concerns or changes that were made based on this review.

We consulted with the university’s Genetically Modified Organism safety officer with regards to our project. The University of Glasgow has a clearly defined policy regarding work with GMOs. This can be viewed here

c) Will / did you receive any biosafety and/or lab training before beginning your project? If so, describe this training.

Prior to the start of our time in the lab, each of us attended a three day training course designed to introduce us to the essential techniques we would need to work safely in the weeks to come. We were also given handy practical tips, such as safe handling and storage of bacteria, care when using reagents such as SybrSafe and working aseptically.

On our first day in the lab, we were given an in depth safety demonstration on how to use the equipment by David Somerville, head of the Microbiology Teaching Lab. After setting up the equipment in our lab, we had a meeting with our building’s safety officer who discussed our project and the rules of the building we would be working in. We then went on a tour of the building, to ensure that everyone knew the location of fire exits, eye wash baths, first aid boxes and where we could find a first aider if so required. We spent the rest of our first day reading and signing the relevant COSHH forms. These were then compiled into a folder which was kept in an accessible place along with a copy of the instructions of all the equipment we would be using, and the data sheets for chemicals.

d) Does your country have national biosafety regulations or guidelines? If so, provide a link to them online if possible.

Yes, the UK has a number of national biosafety regulations and guidelines.

The Genetically Modified Organisms (Contained Use) Regulations (2000)

This is available here.

Biosafety level 1 & 2 - A table of practical guidelines for working with organisms of biosafety level 1 & 2

WHO Laboratory biosafety Manual, pp9-19 - A comprehensive list of instructions for working with biosafety level 1 & 2 organisms

Question 4:

Do you have other ideas on how to deal with safety or security issues that could be useful for future iGEM competitions? How could parts, devices and systems be made even safer through biosafety engineering?

We propose that teams working on light induced promoters should include the additional safety measure of using a chemically induced promoter. This would mean that, in the event of the microbe escaping the lab, the likelihood of it meeting the chemical (in the correct concentration and volume) that induces the promoter is extremely low. It would therefore never become activated.

To further the idea of a chemically activated promoter, we have been working with a the pBAD promoter. Not only is this only activated by the sugar arabinose, it is also inactivated by the sugar glucose - a substance which is found abundantly in humans. This has improved the safety of our biobricks as if we did happen to accidentally ingest any bacteria transformed with our constructs they would be unable to trigger their specific biobrick gene response.